The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / JAK Inhibitors: Are All Promises Fulfilled?

JAK Inhibitors: Are All Promises Fulfilled?

July 22, 2022 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

EULAR 2022 (VIRTUAL)—It’s been 10 years since the first Janus kinase (JAK) inhibitor was approved for the treatment of rheumatoid arthritis (RA) in the U.S., with several others following suit. Hopes were high for JAK inhibitors to revolutionize RA care. So were all promises fulfilled?

You Might Also Like
  • FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
  • Insights into JAK Inhibitor Use
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
Explore This Issue
September 2022
Also By This Author
  • A Young Disease: A Holistic Approach to the Treatment of Antiphospholipid Syndrome

At the 2022 Congress of the European Alliance of Associations for Rheumatology (EULAR), Hendrik Schulze-Koops, MD, PhD, professor, Division of Rheumatology and Clinical Immunology, Ludwig-Maximilians University Munich, Germany, reviewed the data available to answer this question. He focused on JAK inhibitors as a class, as opposed to specific drugs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

JAK Inhibitor Promises

Dr. Schulze-Koops

Dr. Schulze-Koops first delineated promises of JAK inhibitor therapies with help from an ACR Convergence 2021 abstract.1 Taylor et al. conducted surveys to understand why physicians chose JAK inhibitors for certain patients. The most important clinical reason for a physician to prescribe a JAK inhibitor was the hope for strong overall efficacy. This was followed by a desire for a fast onset of action, inhibition of disease progression, strong efficacy as monotherapy and achievement of clinical remission.

Consequently, Dr. Schulze-Koops organized his talk by four JAK inhibitor promises: 1) efficacy; 2) drug survival; 3) safety; and 4) simple mechanism of action.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Promise 1: Efficacy

“Some years ago, it was very apparent that whatever we did with biologics, we had similar ACR20, ACR50, and ACR70 responses across the available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Whether it was tumor necrosis factor-α (TNFα) inhibitors or a non-TNFα inhibitor, we were seeing about a 60–70% ACR20, 30% ACR50 and 20% ACR70 response rates. This is what the JAK inhibitors had to compete with,” Dr. Schulze-Koops explained.2

In 2012, we saw data showing an ACR20 response rate of 59.8% at month three for a JAK inhibitor as monotherapy.3 A year later, we saw data speaking to the efficacy of a JAK inhibitor in combination with methotrexate in patients with moderate-to-severe RA who had failed to respond to TNFα inhibitors. The ACR20 response rate was 41.7% at month three, with a small percentage of patients even achieving Disease Activity Score-28 (DAS28) remission.4

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In 2017, a year-long study demonstrated that a JAK inhibitor in combination with methotrexate worked quickly and better than a TNFα inhibitor, with an increased ACR20 response rate at month three with the JAK inhibitor vs. adalimumab (70% vs. 61%, P=0.014). Responses were maintained for at least a year.5

Pages: 1 2 3 4 5 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: EULAR, EULAR 2022, JAK inhibitors, jakinibs, janus kinase inhibitor, Rheumatoid Arthritis (RA)Issue: September 2022

You Might Also Like:
  • FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
  • Insights into JAK Inhibitor Use
  • Researchers Give Update on Janus Kinase (JAK) Inhibitors
  • Where Will Kinase Inhibitors Fit into the RA Treatment Mix?

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)